Opinion|Videos|November 20, 2026

Adoption, Payer Priorities, and What's Next in EGFR Exon 20 NSCLC

Author(s)Helena Yu, MD

Cost, route of administration, tolerability, and care team experience all shape adoption, while anticipated approvals of oral options point toward a more crowded first-line landscape.

This final episode, "Adoption, Payer Priorities, and What's Next in EGFR Exon 20 NSCLC," features Dr. Yu considering how practices, payers, and clinicians will navigate an expanding set of first-line choices.

Dr. Yu describes adoption decisions as multifaceted. Drug cost is central, since amivantamab, sunvozertinib, and zipalertinib are all expensive novel therapies. Route of administration matters too. Sunvozertinib and zipalertinib are taken at home, whereas chemotherapy and amivantamab require infusion or injection in clinic. Tolerability also shapes utilization, because well-tolerated regimens need fewer resources to manage toxicities. Her center has moved all amivantamab from intravenous to subcutaneous dosing, replacing a roughly 4-hour infusion with a 10-minute injection. That change has improved chair availability and clinic throughput.

On community adoption of first-line amivantamab plus chemotherapy, Dr. Yu acknowledges a steep learning curve. Its unique toxicity profile requires education and experience for physicians and support staff. Still, it is the only approved first-line targeted option for exon 20 insertions and is clearly better than chemotherapy alone. Because these patients respond poorly to chemotherapy alone, she perceives uptake as quite significant.

Speaking outside her direct experience, Dr. Yu suggests that payers and P&T committees would weigh efficacy first, since durable disease control prevents costly cancer-related complications. Route of administration would follow, contrasting visits every 3 months for oral therapy with visits every 3 weeks for clinic-based regimens. Prophylactic medication costs and specialist care, such as oncodermatology for significant rash, would also factor in.

Looking ahead, she notes that the zipalertinib application has a PDUFA date she believes falls in February, initially for second-line use. A later first-line approval is possible given the published REZILIENT3 data, and sunvozertinib may see its label expanded to first line. She expects many patients to favor oral options. Choosing between monotherapy and combination with chemotherapy will be personal, balancing small efficacy differences against side effect concerns. She calls zipalertinib plus chemotherapy a very reasonable starting point. As the field grows crowded, sequencing and resistance will define the next questions.

Thank you for watching this AJMC Post-Conference Perspectives series on EGFR exon 20 insertion–mutated non-small cell lung cancer. Please subscribe to our eNewsletter for information on upcoming video series.


Related to this article